Around 90 women with advanced cervical cancer in the UK could soon be eligible for treatment with Regeneron's immunotherapy Libtayo (cemiplimab) each year, after the drug was officially recommended for use by the NHS in England and Wales.
In its final draft guidance, the reimbursement authority NICE gave a green light to the PD-1 inhibitor for the treatment of recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy. Patients are eligible for Libtayo if they have not had prior immunotherapy, and they can receive up to 16 six-week treatment cycles. Currently, the only treatment option available to women in this category is single-agent chemotherapy.
Aligning with Scotland
This new guidance brings England into line with Scotland, which recommended Libtayo for the same indication in early 2025. Wales and Northern Ireland are likely to follow suit following NICE's endorsement.
Despite the substantial impact of the HPV vaccination campaign in the UK-which has resulted in zero young women dying of cervical cancer between 2020 and 2024, according to data published in The Lancet-cervical cancer remains the 14th most common cancer affecting women in the UK. There are approximately 3,300 new cases each year, with HPV thought to be responsible for 99% of cases.
A Meaningful Improvement in Survival
"Recurrent or metastatic cervical cancer has a substantial impact on length and quality of life," NICE noted in a statement regarding the decision. "Living with the condition is physically and emotionally exhausting, and when the cancer recurs or spreads again, treatment options become increasingly limited."
The agency added, "Our independent committee concluded that it offers a meaningful improvement in prolonging the time before the disease gets worse and in overall survival compared with standard chemotherapy."
Clinical evidence supporting this decision stems from the EMPOWER Cervical-1 trial. Over a follow-up period of nearly four years, the trial revealed a median overall survival of 11.7 months in the Libtayo arm, compared to 8.5 months with chemotherapy. At the two-year mark, approximately 28% of Libtayo-treated women were still alive, compared to less than 12% in the chemotherapy arm.
Expanding Libtayo's Footprint
Libtayo is already utilized by the NHS in England for two forms of skin cancer-cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC)-in patients who have relapsed after prior treatment. While considered a late entrant into the highly competitive PD-1/PD-L1 inhibitor category, the drug has enjoyed a surge in sales over the past year following approval for adjuvant use in CSCC, a niche largely free of competition from other drugs in the class.
Clinical Data Supporting the NICE Recommendation
The National Institute for Health and Care Excellence (NICE) has recommended the immunotherapy drug Libtayo (cemiplimab) for patients with advanced, recurrent cervical cancer who have previously undergone chemotherapy. The recommendation is supported by data from clinical trials showing that Libtayo significantly extends overall survival compared to standard chemotherapy, offering a vital new treatment option for a patient population with historically limited options.
This decision makes Libtayo routinely available on the NHS in England and Wales, and serves as an important benchmark for other European health systems, including Ireland's National Centre for Pharmacoeconomics (NCPE), as they evaluate the cost-effectiveness and funding of the drug for local patients.
Frequently Asked Questions
What type of drug is Libtayo (cemiplimab)?
Libtayo is an immunotherapy drug known as a PD-1 inhibitor, which works by helping the patient's own immune system detect and kill cancer cells.
Who is eligible for Libtayo under the NICE guidelines?
Adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-based chemotherapy are eligible.
How does Libtayo compare to standard chemotherapy in clinical trials?
Clinical data showed that Libtayo reduced the risk of death by 31% and extended median overall survival by several months compared to investigator-choice chemotherapy.
Frequently Asked Questions
How is Libtayo administered to patients?
Libtayo is administered as an intravenous infusion in a clinical setting, typically once every three weeks, under the supervision of an oncologist.
What are the most common side effects of Libtayo?
Common side effects include fatigue, musculoskeletal pain, rash, diarrhea, and immune-mediated adverse reactions affecting organs like the lungs or thyroid.
Does the NICE recommendation apply to all of the UK?
The recommendation applies directly to NHS England and NHS Wales, with Northern Ireland and Scotland typically conducting aligned health-technology reviews.
Frequently Asked Questions
How is Libtayo administered to patients?
Libtayo is administered as an intravenous infusion in a clinical setting, typically once every three weeks, under the supervision of an oncologist.
What are the most common side effects of Libtayo?
Common side effects include fatigue, musculoskeletal pain, rash, diarrhea, and immune-mediated adverse reactions affecting organs like the lungs or thyroid.
Does the NICE recommendation apply to all of the UK?
The recommendation applies directly to NHS England and NHS Wales, with Northern Ireland and Scotland typically conducting aligned health-technology reviews.
